Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

Fig. 2

Kaplan-Meier survival analysis in osteosarcomas. a Overall survival and relapse-free survival according to tumor stage and immunohistochemical expression of PARP1, γH2AX, BRCA1, and BRCA2 in 35 osteosarcoma patients. b Overall survival and relapse-free survival according to immunohistochemical expression of PARP1, γH2AX, BRCA1, and BRCA2 in low-stage (stage I and II) osteosarcoma patients

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us